NCT06958120 Bilateral Ultrasound Guided Superficial Parasternal Intercostal Plane Block Versus Erector Spinae Plane Block
| NCT ID | NCT06958120 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cairo University |
| Condition | CHD - Congenital Heart Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-06-01 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-06-01 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Group (A): This group will receive fentanyl infusion at a dose of (0.5μg/kg/h) all through the whole operation plus ultrasound guided bilateral superficial parasternal intercostal Plane block which will be done by injecting 0.4ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side3. Group (B): This group will receive fentanyl infusion at a dose of (0.5μg/kg/h) all through the whole operation plus Ultrasound guided bilateral ESPB which will be done by injecting 0.4ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side .
Eligibility Criteria
Inclusion Criteria: * RACHS-1: Categories 1, 2 and 3 * Patients undergoing corrective cardiac surgeries with midline sternotomy incision. * Redo surgeries. Exclusion Criteria: * Patients whose parents or legal guardians refuse to participate. * Preoperative mechanical ventilation. * Preoperative inotropic drug infusion. * Coagulopathy. * Allergy to any of the studied drugs. * Severe pulmonary hypertension (\> 70 mmHg).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06958120 clinical trial?
This trial is open to participants of all sexes, aged 6 Months or older, up to 4 Years, studying CHD - Congenital Heart Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06958120 currently recruiting?
Yes, NCT06958120 is actively recruiting participants. Contact the research team at dr_memoo2003@hotmail.com for enrollment information.
Where is the NCT06958120 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT06958120 clinical trial?
NCT06958120 is sponsored by Cairo University. The trial plans to enroll 50 participants.